1 study found for:    23724867 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04);   Drug: Ipilimumab

Indicates status has not been verified in more than two years